High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy

AIDS

Volumn 17, Issue 8, 2003, Pages 1173-1178

  Alonso Villaverde, Carlos ^a,b   Segues, Teresa ^a   Coll Crespo, Blai ^a   Pérez Bernalte, Rosa ^a   Rabassa, Antoni ^a   Gomila, Maika ^a   Parra, Sandra ^a   Gozález Esteban, M Asunción ^a   Jiménez Expósito, Ma Jesús ^a   Masana, Lluis ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b Sant Joan University Hospital   (Spain)

Author keywords

Apolipoprotein A1; HDL cholesterol; HIV; p17 Gag; Sequence similarity; Structure homology; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A1; CHOLESTEROL; GAG PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN GAG P17; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CHRONOSEQUENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NONBIOLOGICAL MODEL; OPPORTUNISTIC INFECTION; PATIENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; RESPONSE TIME; RETROSPECTIVE STUDY; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STRUCTURAL HOMOLOGY; SYNCYTIUM; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; FEMALE; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV-1; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEQUENCE ALIGNMENT; VIRAL LOAD; VIRUS REPLICATION;

EID: 0038544052     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305230-00009     Document Type: Article

References (44)

1. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-1883.
2. Rauchhaus M, Coats A, Anker D. The endotoxin-lipoprotein hypothesis. Lancet 2000, 356:930-933.
3. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995, 36:211-228.
4. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001, 21:481-488.
5. Kwiterovich PO Jr. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 1998, 82:13Q-21Q.
6. De Sanctis JB, Blanca I, Bianco NE. Secretion of cytokines by natural killer cells primed with interleukin-2 and stimulated with different lipoproteins. Immunology 1997, 90:526-533.
7. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995, 11:1987-1994.
8. Sandstrom PA, Murray J, Folks TM, Diamond AM. Antioxidant defenses influence HIV-1 replication and associated cytopathic effects. Free Radic Biol Med 1998, 9:1485-1491.
9. Poli G. Laureate ESCI award for excellence in clinical science 1999. Cytokines and the human immunodeficiency virus: from bench to bedside. Eur J Clin Invest 1999, 8:723-732.
10. Woodman SE, Benveniste EN, Nath A, Berman JW. Human immunodeficiency virus type 1 TAT protein induces adhesion molecule expression in astrocytes. J Neurovirol 1999, 6:678-684.
11. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001, 98:13925-13930.
12. Rothblat GH, Mahlberg FH, Johnson WJ, Phillips MC. Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. J Lipid Res 1992, 33:1091-1097.
13. Srinivas RV, Venkatachalapathi YV, Rui Z, Owens RJ, Gupta KB, Srinivas SK, et al. Inhibition of virus-induced cell fusion by apolipoprotein A-I and its amphipathic peptide analogs. J Cell Biochem 1991, 45:224-237.
14. Owens BJ, Anantharamaiah GM, Kahlon JB, Srinivas RV, Compans RW, Segrest JP. Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J Clin Invest 1990, 86:1142-1150.
15. Simo JM, Castellano I, Ferre N, Joven J, Camps J. Evaluation of a homogeneous assay for high-density lipoprotein cholesterol: limitations in patients with cardiovascular, renal, and hepatic disorders. Clin Chem 1998, 6:1233-1241.
16. Bairoch A, Apweiler R. The SWISS-PROT protein sequence databbase and TrEMBL in 2000. Nucl Acids Res 2000, 28:45-48.
17. Higgins DG, Sharp PM. Fast and sensitive multiple sequence alignments on a microcomputer. Comput Appl Biosci 1989, 5:151-153.
18. Borhani DW, Rogers PD, Engler JA, Brouillette CG. Crystal structure of truncated human apolipoprotein A-I suggest a lipid-bound conformation. Proc Natl Acad Sci USA 1997, 94:12291-12296.
19. Massiah MA, Starich MR, Paschall C, Summers MF, Christensen AM, Sundquist WI. Three-dimensional structure of the human inmunodeficiency virus type 1 matrix protein. J Mol Biol 1994, 244:198-223.
20. Hill PC, Worthylake D, Bancroft DP, Christensen AM. Crystal structures of the trimeric human immunodefiency virus type 1 matrix protein: Implications for membrane association and assembly. Proc Natl Acad Sci U S A 1996, 93:3099-3104.
21. Berman HM, Westbrook J, Zeng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucl Acids Res 2000, 28:235-242.
22. Treitinger A, Spada C, Verdi JC, Miranda AF, Oliveira OV, Silveira MV, et al. Decreased antioxidant defence in individuals infected by the human immunodeficiency virus. Eur J Clin Invest 2000, 5:454-459.
23. Allard JP, Aghdassi E, Chau J, Tam C, Kovacs CM, Salit IE, Walmsley SL. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. Eur J Clin Invest 1998, 12:1653-1659.
24. Sandstrom PA, Murray J, Folks TM, Diamond AM. Antioxidant defenses influence HIV-1 replication and associated cytopathic effects. Free Radic Biol Med 1998, 9:1485-1491.
25. Caggiari L, Zanussi S, Bortolin MT, D'A ndrea M, Nasti G, Simonelli C, et al. Effects of therapy with highly active antiretroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients. Clin Exp Immunol 2000, 120:101-106.
26. Biswas P, Mantelli B, Delfanti F, Cota M, Vallanti G, de Filippi C, et al. Tumor necrosis factor-alpha drives HIV-1 replication in U937 cell clones and upregulates CXCR4. Cytokine 2001, 13:55-59.
27. Luchoomun J, Theret N, Clavey V, Duchateau P, Rosseneu M, Brasseur R, et al. Structural domain of apolipoprotein A-1 involved in its interaction with cells. Biochim Biophys Acta 1994, 1212:319-326.
28. Sviridov D, Pyle L, Fidge N. Identification of a sequence of apolipoprotein A-1 associated with the efflux of intracellular cholesterol to human serum and apolipoprotein A-I containing particles. Biochemistry 1996, 35:189-196.
29. Fielding PE, Kawano M, Catapano AL, Zoppo A, Marcovina S, Fielding CJ. Unique epitope of apolipoprotein A-I expressed in pre-beta-1 high density lipoprotein and its role in the catalyzed efflux of cellular cholesterol. Biochemistry 1994, 33:6981-6985.
30. Frank PG, N'Guyen D, Franklin V, Neville T, Desforges M, Rassart E, et al. Importance of central alpha-helices of human apolipoprotein A-I in the maturation of high density lipoproteins. Biochemistry 1998, 37:13902-13909.
31. Roosbeek S, Vanloo B, Duverger N, Caster H, Breyne J, De Beun I, et al. Three arginine residues in apolipoprotein A-I are critical for activation of lecithin:cholesterol acyltransferase. J Lipid Res 2001, 42:31-40.
32. Frank PG, Bergeron J, Emmanuel F, Lavigne JP, Sparks DL, Denefle P, et al. Deletion of central alpha-helices in human apolipoprotein A-I: effect on phospholipid association. Biochemistry 1997, 36:1798-1806.
33. Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998, 19:1-15.
34. Cannon PM, Matthews S, Clark, N, Byles ED, Iourin O, Hockley DJ, et al. Structure-function studies of the human immunodefiency virus type 1 matrix protein, p17. J Virol 1997, 71:3474-3483.
35. Gonzales SA, Alfranchino JL. Mutational analysis of the conserved cysteine residues in the simian immunodeficiency virus type 1 matrix protein. Virology 1995, 210:501-507.
36. Rao Z, Belyaev EF, Roy P, Jones IM, Stuart DI. Crystal stucture of SIV matrix antigen and implications for viral assembly. Nature 1995, 378:743-747.
37. Morikawa Y, Zhang WH, Hockley DJ, Nermut MV, Jones IM. Detection of a trimeric human immunodeficiency virus type 1 Gag intermediate is dependent on sequences in the matrix protein, p17. J Virol 1998, 72:7659-7663.
38. Freed EO, Oreinstein JM, Buckler-White AJ, Martin MA. Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol 1994, 68:5311-5320.
39. Morikawa Y, Kishi T, Zhang H, Nermut MV, Hockley DJ, Jones IM. A molecular determinant of the human immunodeficiency virus particle assembly located in matrix p17 antigen. J Virol 1995, 69:4519-4523.
40. Reicin AS, Palk S, Berkowitz RD, Luban J, Lowy I, Golf SP. Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J Virol 1995, 69:642-650.
41. Chazal N, Gay B, Carriere C, Tournier J, Boulanger P. Human immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway. J Virol 1995, 69:365-375.
42. Ota A, Liu X, Fujio H, Sakato N, Ueda S. Random expression of human immunodeficiency virus-1 (HIV-1) p17 (epitopes) on the surface of the HIV-1-infected cell. Hybridoma 1998, 1:73-75.
43. Gillote KL, Davidson WS, Lund-Katz, Rothblat GH, Phillips MC. Removal of cellular cholesterol by pre-beta-HDL involves plasma membrane microsolubilization. J Lipid Res 1998, 39:1918-1928.
44. Gillote KL, Zaiou M, Lund-Katz S, Annantharamaiah GM, Holvoet P, Dhoest A, et al. Apolipoprotein-mediated plasma membrane microsolubilization. Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. J Biol Chem 1999, 22:2021-2028.